Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Intrathecal Chemotherapy

Selection of Cytostatic Agents

Abstract

Selection of cytostatic agents for intrathecal administration is the subject of this paper.

Both the toxic side effects—destruction of blood-brain barrier and change of body weight—and the cytostatic effects on intracranially transplanted Yoshida ascites sarcoma were investigated of intrathecal administration of various cytostatic agents. As a result, it may be concluded that Methotrexate and Endoxan and lower dose of mitomycin C are suitable drugs for intrathecal chemotherapy.

Based on these findings, clinical cases of malignant brain tumours were treated with intrathecal chemotherapy.

Grateful acknowledgement is made to Professor Dennosuke Jinnai for his constant interest and guidance in this investigation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayakawa, T., Yamada, R., Kanai, N. et al. Intrathecal Chemotherapy. Br J Cancer 24, 489–497 (1970). https://doi.org/10.1038/bjc.1970.59

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1970.59

This article is cited by

Search

Quick links